For example, the reduction in postprandial glycaemia induced by GLP-1RAs [12] and dipeptidyl peptidase-4 (DPP-4) inhibitors [13, 14] is greater in those T2D patients in whom GE is relatively more rapid at baseline. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.